If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"true","masked_subject":"true","masking_description":"This will be a double-blind methodology in adult PLHIV.","no_masking":"false"},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"N/A","arm_groups":[{"arm_group_label":"Subjects with HIV infection","arm_group_description":"HIV sero-positive subjects who are treated with antiretroviral therapy will be included in this positive perspectives survey.","arm_type":"Experimental"}],"assignment":"","brief_summary":"Antiretroviral treatment is presented as a life-long necessity to the Human immunodeficiency virus (HIV)-positive subjects. Subjects with HIV face many challenges managing their HIV treatment, including regimen complexity and pill burden, drug toxicity, side effects, the frequency of visits to their healthcare provider (HCP) and the quality of subject care and support. A Positive Perspectives survey was conducted on People Living with the Human Immunodeficiency Virus (PLHIV) in 9 countries in 2016-2017. This new survey aims to expand on themes explored in that survey, give greater focus to issues surrounding treatment satisfaction, challenges and needs, and to include a wider and more diverse range of countries. This study consists of main survey and exploratory phase. Main survey will be an on/off line semi-structured self-completion survey of PLHIV in 25 countries. Exploratory phase will include desk research, knowledge audit and Local Operating Company Engagement. Data will be collected through direct electronic means in the following ways: Computer-Assisted Web Interviews, Computer-Assisted Telephone Interviews and Computer-Assisted Personal Interviews.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Positive Perspectives Survey","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"05/20/2020 14:07:00","criteria":"Inclusion Criteria:\n - Be willing and able to provide electronic/verbal informed consent to participate based on survey description, including use of any data provided and Adverse Event Reporting requirements.\n - Male or female, aged 18 to 84 years.\n - Self-identify as having been diagnosed by a doctor or other HCP as being HIV sero-positive.\n - Are, at the time of participation, currently being treated with an antiretroviral drug/s.\n - Resident of countries participating in the survey.\n - Able to read, speak, and understand English or other languages that the survey is available in.\n\nExclusion Criteria:\n - Not applicable.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"N/A","display_phase_internal":"PHASE_NA","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"2015","exclusion":"","gender":"All","gender_based":"No","gender_description":"","healthy_volunteers":"No","id":"a48bae2a-ecff-58c0-bd31-ab67d53a21a8","internal":{"content":null,"contentDigest":"42b620af08602111dff311372a4e9be8","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\n - Be willing and able to provide electronic/verbal informed consent to participate based on survey description, including use of any data provided and Adverse Event Reporting requirements.\n - Male or female, aged 18 to 84 years.\n - Self-identify as having been diagnosed by a doctor or other HCP as being HIV sero-positive.\n - Are, at the time of participation, currently being treated with an antiretroviral drug/s.\n - Resident of countries participating in the survey.\n - Able to read, speak, and understand English or other languages that the survey is available in.\n\nExclusion Criteria:\n - Not applicable.","interventions":[],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["HIV","PLHIV","Antiretroviral therapy","Perspectives survey"],"last_follow_up_date":"02/05/2020 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"84 Years","maximum_age":"84","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"05/20/2020 14:07:00","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"None Retained","number_of_groups":"1","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Prospective"},"official_title":"Positive Perspectives Survey","org_study_id":"212268","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"No","fda_regulated_drug":"No","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"N/A","primary_compl_date":"02/05/2020 00:00:00","primary_outcomes":[{"outcome_description":"Subjects who agree/strongly agree that there is room for improving the way their HIV is managed will be assessed.","outcome_measure":"Percentage of PLHIV who agree/strongly agree that there is room for improving the way their HIV is managed","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who agree/strongly agree that they are actively involved in decisions concerning their HIV treatment will be assessed.","outcome_measure":"Percentage of PLHIV who agree/strongly agree that they are actively involved in decisions concerning their HIV treatment","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects whose status is only known to their HIV HCPs or their close friends/family and would very uncomfortable disclosing beyond that will be assessed.","outcome_measure":"Percentage of PLHIV whose status is only known to their HIV HCPs or their close friends/family and would very uncomfortable disclosing beyond that","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who are not very/not at all comfortable in raising issues of concern to them with their main HIV care provider will be assessed.","outcome_measure":"Percentage of PLHIV who are not very/not at all comfortable in raising issues of concern to them with their main HIV care provider","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who worry about the long-term effects of HIV medications will be assessed.","outcome_measure":"Percentage of PLHIV who worry about the long-term effects of HIV medications","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who are dissatisfied with their current HIV medication will be assessed.","outcome_measure":"Percentage of PLHIV who are dissatisfied with their current HIV medication","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who have difficulty adhering to their current oral antiretroviral therapy regimen in the past month will be assessed.","outcome_measure":"Percentage of PLHIV who have difficulty adhering to their current oral antiretroviral therapy regimen in the past month","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"Subjects who agree/strongly agree that there is room for improving the way their HIV is managed will be assessed among different cohorts.","outcome_measure":"Percentage of PLHIV among different cohorts who agree/strongly agree that there is room for improving the way their HIV is managed","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who agree/strongly agree that they are actively involved in decisions concerning their HIV treatment will be assessed among different cohorts.","outcome_measure":"Percentage of PLHIV among different cohorts who agree/strongly agree that they are actively involved in decisions concerning their HIV treatment","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects whose status is only known to their HIV HCPs or their close friends/family and would very uncomfortable disclosing beyond that will be assessed among different cohorts.","outcome_measure":"Percentage of PLHIV among different cohorts whose status is only known to their HIV HCPs or their close friends/family and would very uncomfortable disclosing beyond that","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who are not very/not at all comfortable in raising issues of concern to them with their main HIV care provider will be assessed among different cohorts.","outcome_measure":"Percentage of PLHIV among different cohorts who are not very/not at all comfortable in raising issues of concern to them with their main HIV care provider","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who worry about the long-term effects of HIV medications will be assessed among different cohorts.","outcome_measure":"Percentage of PLHIV among different cohorts who worry about the long-term effects of HIV medications","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who are dissatisfied with their current HIV medication will be assessed among different cohorts.","outcome_measure":"Percentage of PLHIV among different cohorts who are dissatisfied with their current HIV medication","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who have difficulty adhering to their current oral antiretroviral therapy regimen in the past month will be assessed among different cohorts.","outcome_measure":"Percentage of PLHIV among different cohorts who have difficulty adhering to their current oral antiretroviral therapy regimen in the past month","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who agree/strongly agree that there is room for improving the way their HIV is managed will be assessed among different countries or geographical regions.","outcome_measure":"Percentage of PLHIV among different countries or geographical regions who agree/strongly agree that there is room for improving the way their HIV is managed","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who agree/strongly agree that they are actively involved in decisions concerning their HIV treatment will be assessed among different countries or geographical regions.","outcome_measure":"Percentage of PLHIV among different countries or geographical regions who agree/strongly agree that they are actively involved in decisions concerning their HIV treatment","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects whose status is only known to their HIV HCPs or their close friends/family and would very uncomfortable disclosing beyond that will be assessed among different countries or geographical regions.","outcome_measure":"Percentage of PLHIV among different countries or geographical regions whose status is only known to their HIV HCPs or their close friends/family and would very uncomfortable disclosing beyond that","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who are not very/not at all comfortable in raising issues of concern to them with their main HIV care provider will be assessed among different countries or geographical regions.","outcome_measure":"Percentage of PLHIV among different countries or geographical regions who are not very/not at all comfortable in raising issues of concern to them with their main HIV care provider","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who worry about the long-term effects of HIV medications will be assessed among different countries or geographical regions.","outcome_measure":"Percentage of PLHIV among different countries or geographical regions who worry about the long-term effects of HIV medications","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who are dissatisfied with their current HIV medication will be assessed among different countries or geographical regions.","outcome_measure":"Percentage of PLHIV among different countries or geographical regions who are dissatisfied with their current HIV medication","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null},{"outcome_description":"Subjects who have difficulty adhering to their current oral antiretroviral therapy regimen in the past month will be assessed among different countries or geographical regions.","outcome_measure":"Percentage of PLHIV among different countries or geographical regions who have difficulty adhering to their current oral antiretroviral therapy regimen in the past month","outcome_time_frame":"Approximately 3 months","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["Ipsos"]},"start_date":"04/03/2019 00:00:00","study_type":"Observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"212268"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}